Global Health Policy Blog

CGD experts offer ideas and analysis on global health issues and how better policies can improve well-being for everyone. Also check out our Views from the Center blog and US Development Policy blog.

 

What is an Advance Market Commitment?

CGDThe essence of an advance market commitment is that sponsors would guarantee that, if a suitable vaccine is developed, they will pay for it to be bought and used in developing countries.

Clinical Trials for New TB Vaccine Begin

AERASThe Aeras Global TB Vaccine Foundation and the David Geffen School of Medicine at UCLA today announced they have begun the first clinical trial of a live recombinant tuberculosis vaccine in the U.S.

The Global Fund to Fight AIDS, TB, and Malaria: Performance and Vision

The Global Fund to Fight AIDS, Tuberculosis, and Malaria (GFATM) was established very quickly in 2001 in response to a widespread perception that a rapid scale-up in financing was critical in the fight against the three diseases. Since it began operations in January 2002, GFATM has made important progress. It has raised substantial funding and become the world’s largest donor for TB and malaria. 70% of the programs reaching the two-year renewal stage are showing solid results. Rwanda, for example, has put over 4,000 people on ARV treatment, more than double its program target, and GFATM programs in aggregate have financed ARV treatment for 130,000 people to date.

About Vaccines for Development

CGDImmunization is one of the safest ways to reduce disease and poverty in developing countries. But 3 million people die every year of vaccine-preventable diseases; and that will likely rise to 4.5 million when rotavirus and pneumococcus vaccines are available, if past experience is any guide. And progress towards vaccines suitable for HIV, malaria and tuberculosis is painfully slow.

Pages

Global Health Policy Blog

Tags

Experts